17 research outputs found
Response of Microorganisms to Hot Crude Oil Spills on a Subarctic Taiga Soil
This study was conducted on the short-term effects of seasonal spills of hot Prudhoe Bay crude oil on microorganisms in a taiga soil in interior Alaska. Following a winter spill, the filamentous fungal populations were inhibited whereas the heterotrophic bacterial populations were stimulated. After a summer spill there was an initial depression of both the filamentous fungal and bacterial populations followed by a general enhancement. In both oil spill plots, yeasts; along with the denitrifying, proteolytic, oil-utilizing, and cellulose-utilizing microorganisms; were favorably affected by the oil. Soil respiration was also enhanced in the oiled plots. An extended period of study is required to fully evaluate the impact of oil on the soil microflora and the role of these microorganisms in recovery of oil-inundated areas in subarctic ecosystems
From Data to Software to Science with the Rubin Observatory LSST
The Vera C. Rubin Observatory Legacy Survey of Space and Time (LSST) dataset
will dramatically alter our understanding of the Universe, from the origins of
the Solar System to the nature of dark matter and dark energy. Much of this
research will depend on the existence of robust, tested, and scalable
algorithms, software, and services. Identifying and developing such tools ahead
of time has the potential to significantly accelerate the delivery of early
science from LSST. Developing these collaboratively, and making them broadly
available, can enable more inclusive and equitable collaboration on LSST
science.
To facilitate such opportunities, a community workshop entitled "From Data to
Software to Science with the Rubin Observatory LSST" was organized by the LSST
Interdisciplinary Network for Collaboration and Computing (LINCC) and partners,
and held at the Flatiron Institute in New York, March 28-30th 2022. The
workshop included over 50 in-person attendees invited from over 300
applications. It identified seven key software areas of need: (i) scalable
cross-matching and distributed joining of catalogs, (ii) robust photometric
redshift determination, (iii) software for determination of selection
functions, (iv) frameworks for scalable time-series analyses, (v) services for
image access and reprocessing at scale, (vi) object image access (cutouts) and
analysis at scale, and (vii) scalable job execution systems.
This white paper summarizes the discussions of this workshop. It considers
the motivating science use cases, identified cross-cutting algorithms,
software, and services, their high-level technical specifications, and the
principles of inclusive collaborations needed to develop them. We provide it as
a useful roadmap of needs, as well as to spur action and collaboration between
groups and individuals looking to develop reusable software for early LSST
science.Comment: White paper from "From Data to Software to Science with the Rubin
Observatory LSST" worksho
Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND) : a multicentre, parallel, randomised controlled trial in the UK
Background Motor neuron disease is a progressive, fatal neurodegenerative disease for which there is no cure. Acceptance and Commitment Therapy (ACT) is a psychological therapy incorporating acceptance, mindfulness, and behaviour change techniques. We aimed to evaluate the effectiveness of ACT plus usual care, compared with usual care alone, for improving quality of life in people with motor neuron disease. Methods We conducted a parallel, multicentre, two-arm randomised controlled trial in 16 UK motor neuron disease care centres or clinics. Eligible participants were aged 18 years or older with a diagnosis of definite or laboratory-supported probable, clinically probable, or possible familial or sporadic amyotrophic lateral sclerosis; progressive muscular atrophy; or primary lateral sclerosis; which met the World Federation of Neurology's El Escorial diagnostic criteria. Participants were randomly assigned (1:1) to receive up to eight sessions of ACT adapted for people with motor neuron disease plus usual care or usual care alone by a web-based system, stratified by site. Participants were followed up at 6 months and 9 months post-randomisation. Outcome assessors and trial statisticians were masked to treatment allocation. The primary outcome was quality of life using the McGill Quality of Life Questionnaire-Revised (MQOL-R) at 6 months post-randomisation. Primary analyses were multi-level modelling and modified intention to treat among participants with available data. This trial was pre-registered with the ISRCTN Registry (ISRCTN12655391). Findings Between Sept 18, 2019, and Aug 31, 2022, 435 people with motor neuron disease were approached for the study, of whom 206 (47%) were assessed for eligibility, and 191 were recruited. 97 (51%) participants were randomly assigned to ACT plus usual care and 94 (49%) were assigned to usual care alone. 80 (42%) of 191 participants were female and 111 (58%) were male, and the mean age was 63·1 years (SD 11·0). 155 (81%) participants had primary outcome data at 6 months post-randomisation. After controlling for baseline scores, age, sex, and therapist clustering, ACT plus usual care was superior to usual care alone for quality of life at 6 months (adjusted mean difference on the MQOL-R of 0·66 [95% CI 0·22–1·10]; d=0·46 [0·16–0·77]; p=0·0031). Moderate effect sizes were clinically meaningful. 75 adverse events were reported, 38 of which were serious, but no adverse events were deemed to be associated with the intervention. Interpretation ACT plus usual care is clinically effective for maintaining or improving quality of life in people with motor neuron disease. As further evidence emerges confirming these findings, health-care providers should consider how access to ACT, adapted for the specific needs of people with motor neuron disease, could be provided within motor neuron disease clinical services
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete description of specific immune biomarkers. We present here a comprehensive multi-omic blood atlas for patients with varying COVID-19 severity in an integrated comparison with influenza and sepsis patients versus healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity involved cells, their inflammatory mediators and networks, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism, and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Systems-based integrative analyses including tensor and matrix decomposition of all modalities revealed feature groupings linked with severity and specificity compared to influenza and sepsis. Our approach and blood atlas will support future drug development, clinical trial design, and personalized medicine approaches for COVID-19